Synergistic Antifungal Effects of Honokiol and Fluconazole Against Oral Candida : Implications for Managing Drug‐Resistant Infections
Clinical and Experimental Dental Research · 2026
DOI: 10.1002/cre2.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dental Research, 2026. Verfasst von Maribasappa Karched und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oral Microbiology Laboratory, Department of Bioclinical Sciences, College of Dentistry, Kuwait University, Kuwait City, Kuwait. Hauptthemen laut MEDLINE: Lignans, Biphenyl Compounds, Antifungal Agents, Fluconazole. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Kuwait University, Grant SRUL 01/14., Kuwait University.
Abstract (Originalsprache)
Objectives
Antifungal drug resistance poses a major challenge in treating oral Candida infections. This study aimed to evaluate the antifungal activity of Honokiol, alone and combined with Fluconazole, against oral Candida isolates, and to investigate its mechanism of action via ergosterol biosynthesis inhibition and cell wall disruption. Material and Methods Susceptibility testing was performed using CLSI (M27‐A3) methodology on 16 oral Candida isolates, 8 endodontic isolates, and the reference strain ATCC 24433. Minimum inhibitory concentrations (MICs) of Honokiol and Fluconazole were determined alone and in combination. Ergosterol inhibitory assays and scanning electron microscopy (SEM) were used to assess cell wall integrity and morphological changes.
Results
Honokiol exhibited MICs of 16–64 µg/mL (oral isolates), 16 µg/mL (endodontic isolates), and 32 µg/mL (ATCC 24433). In combination with Fluconazole, Honokiol's MICs decreased 4‐fold (4–16 µg/mL), while Fluconazole's MICs dropped 2‐ to 4‐fold (1–32 µg/mL). Synergy was confirmed by a 95.61% reduction in fungal growth (OD600) compared to controls. SEM revealed severe cell wall distortion, rupture, and cytoplasmic leakage. Honokiol significantly inhibited ergosterol biosynthesis, disrupting cellular integrity.
Conclusion
Honokiol demonstrates potent antifungal activity against oral Candida isolates by targeting ergosterol biosynthesis and compromising cell wall integrity. Its synergistic enhancement of Fluconazole's effect suggests clinical potential as an adjunct therapy, potentially reducing resistance and lowering required drug doses in oral and endodontic candidiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oral Microbiology Laboratory, Department of Bioclinical Sciences, College of Dentistry, Kuwait University, Kuwait City, Kuwait.
- Dasman Diabetes Institute, Kuwait City, Kuwait.
- Department of Restorative Sciences, College of Dentistry, Kuwait University, Kuwait City, Kuwait.
ORCID-Profile: Maribasappa Karched
Förderung
- This study was funded by Kuwait University, Grant SRUL 01/14.
- Kuwait University
Zitieren
APA
Karched, M., Irshad, M., & Behbehani, J. M. (2026). Synergistic Antifungal Effects of Honokiol and Fluconazole Against Oral Candida : Implications for Managing Drug‐Resistant Infections. Clinical and Experimental Dental Research. https://doi.org/10.1002/cre2.70251
Vancouver
Karched M, Irshad M, Behbehani JM. Synergistic Antifungal Effects of Honokiol and Fluconazole Against Oral Candida : Implications for Managing Drug‐Resistant Infections. Clinical and Experimental Dental Research. 2026. doi:10.1002/cre2.70251
BibTeX
@article{Karched2026,
author = {Karched, Maribasappa and Irshad, Mohammad and Behbehani, Jawad M},
title = {Synergistic Antifungal Effects of Honokiol and Fluconazole Against Oral Candida : Implications for Managing Drug‐Resistant Infections},
journal = {Clinical and Experimental Dental Research},
year = {2026},
doi = {10.1002/cre2.70251}
}
EUVIMED